Login (For Administrators)
Who's Online
We have 86 guests online
Statistics since 20 Jan 2009
Content View Hits : 395404
The 10 Most Read Articles
|
|
2011 Apr 22 to 24 - Singapore-ANZICS Intensive Care Forum 2011 |
 |
 |
 |
|
Activity Schedules and Reports -
Overseas Meetings (others)
|
Date: 22 to 24 April 2011; Venue: Singapore
Information from the official website: Over the past two decades, the Intensive Care Communities among Australia, New Zealand and Singapore have enjoyed deepening and mutually constructive ties. In an effort to nurture this relationship to the next level, the Australian and New Zealand Intensive Care Society (ANZICS), and the Society of Intensive Care Medicine ( Singapore ) have come together to co-host the first Singapore-ANZICS Intensive Care Forum 2011.
|
|
Read more...
|
|
2010 July 20 - 23rd CCM Assessment: Information to Trainees and Candidates |
|
|
|
|
Activity Schedules and Reports -
Tutorials and Assessments - CCM Specialty Board
|
|
Date: 20 July 2010; Message from Dr WW Yan, Chairman, Specialty Board of Critical Care Medicine
Dear CCM trainees,
I would like to remind you the following important deadlines for the coming 23rd CCM Assessment held on 20 November 2010.
The deadline for Assessment application is 6 September 2010.
The deadline for Exit dissertation submission is 20 September 2010
|
|
Last Updated on Tuesday, 20 July 2010 11:23 |
|
Read more...
|
|
|
2010 Sep 1 - FDA Drug Safety Communication: Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections |
|
|
|
|
Journal and News Update -
Media & Other Organisations
|
Safety Announcement [09-01-2010]
Quoted from the US FDA: "The U.S. Food and Drug Administration (FDA) is reminding healthcare professionals of an increased mortality risk associated with the use of the intravenous antibacterial Tygacil (tigecycline) compared to that of other drugs used to treat a variety of serious infections. The increased risk was determined using a pooled analysis of clinical trials. The cause of the excess death in these trials is often uncertain, but it is likely that most deaths in patients with these severe infections were related to progression of the infection."
|
|
Read more...
|
|
2010 Sep 1 - Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial |
|
|
|
|
Journal and News Update -
Lancet and the Lancet series of journals
|
Dr Shamir R Mehta MD a , Jean-Francois Tanguay MD b, John W Eikelboom MD a, Sanjit S Jolly MD a, Prof Campbell D Joyner MD c, Christopher B Granger MD d, Prof David P Faxon MD e, Hans-Jurgen Rupprecht MD f, Prof Andrzej Budaj MD g, Alvaro Avezum MD h, Prof Petr Widimsky MD i q, Prof Philippe Gabriel Steg MD j, Prof Jean-Pierre Bassand MD k, Gilles Montalescot MD l, Carlos Macaya MD m, Giuseppe Di Pasquale MD n, Kari Niemela MD r, Andrew E Ajani MD o, Prof Harvey D White MD p, Susan Chrolavicius BA a, Peggy Gao MSc a, Prof Keith AA Fox MBChB s, Prof Salim Yusuf MBBS a, on behalf of the CURRENT-OASIS 7 trial investigators‡. The Lancet, Early Online Publication, 1 September 2010
Background
Clopidogrel and aspirin are the most commonly used antiplatelet therapies for percutaneous coronary intervention (PCI). We assessed the effect of various clopidogrel and aspirin regimens in prevention of major cardiovascular events and stent thrombosis in patients undergoing PCI.
|
|
Read more...
|
|
2010 Sep 1 - Lancet Comment: Acute coronary syndromes: finding meaning in OASIS 7 |
|
|
|
|
Journal and News Update -
Lancet and the Lancet series of journals
|
Gregg W Stone a. The Lancet, Early Online Publication, 1 September 2010doi:10.1016/S0140-6736(10)61262-7Cite or Link Using DOI
Acute coronary syndromes typically arise from rupture of a cholesterol-laden plaque with subsequent thrombotic occlusion of the coronary artery.
|
|
Read more...
|
|
CCMF Sponsorship Recipients |
|
|
|
|
CCM and ICM Development -
Critical Care Medicine Foundation Development
|
In the Extra-Council Meeting held on 25th August 2010, the Critical Care Medicine Foundation approved a new sponsorship.
Click Read More for details.
|
|
Last Updated on Tuesday, 31 August 2010 22:50 |
|
Read more...
|
|
2010 Aug - Prophylaxis, empirical and preemptive treatment of invasive candidiasis |
|
|
|
|
Journal and News Update -
Current Opinion in Critical Care
|
|
Playford EG, Lipman J, Sorrell TC.; Curr Opin Crit Care. 2010 Aug 12.
Purpose of review: Invasive candidiasis remains an important infection for ICU patients, associated with poor clinical outcomes. It has been increasingly recognized that the traditional paradigm of culture-directed antifungal treatment is unsatisfactory, and that earlier antifungal intervention strategies, such as prophylaxis, preemptive therapy, and empiric therapy, are required to improve patient outcomes. The purpose of this review is to summarize the recent supportive evidence for such strategies and to highlight the current challenges in their implementation. |
|
Last Updated on Monday, 30 August 2010 22:56 |
|
Read more...
|
|
2010 Aug 25 - Elective Intra-aortic Balloon Counterpulsation During High-Risk Percutaneous Coronary Intervention: A Randomized Controlled Trial |
|
|
|
|
Journal and News Update -
JAMA & Archives
|
Divaka Perera, MD, MRCP; Rodney Stables, DM, FRCP; Martyn Thomas, MD, FRCP; Jean Booth, MSc; Michael Pitt, MD, FRCP; Daniel Blackman, MD, MRCP; Adam de Belder, MD, FRCP; Simon Redwood, MD, FRCP; for the BCIS-1 Investigators. JAMA. 2010;304(8):867-874. doi:10.1001/jama.2010.1190
Figure. IABP tracing (Photo courtesy: ICU, PYNEH, Hong Kong)
Context Observational studies have previously reported that elective intra-aortic balloon pump (IABP) insertion may improve outcomes following high-risk percutaneous coronary intervention (PCI). To date, this assertion has not been tested in a randomized trial.
|
|
Last Updated on Sunday, 29 August 2010 11:41 |
|
Read more...
|
|
|
2010 Sep 2 - Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes |
|
|
|
|
Journal and News Update -
New England Journal of Medicine
|
The CURRENT–OASIS 7 Investigators. N Engl J Med 2010; 363:930-942, September 2, 2010
Background
Clopidogrel and aspirin are widely used for patients with acute coronary syndromes and those undergoing percutaneous coronary intervention (PCI). However, evidence-based guidelines for dosing have not been established for either agent.
|
|
Last Updated on Thursday, 02 September 2010 11:41 |
|
Read more...
|
|
2010 Sep 2 - NEJM Editorial: Fine-Tuning Therapy for Acute Coronary Syndromes |
|
|
|
|
Journal and News Update -
New England Journal of Medicine
|
Valentin Fuster, M.D., Ph.D. N Engl J Med 2010; 363:976-977, September 2, 2010
Aspirin and clopidogrel are mainstays of therapy for patients presenting with an acute coronary syndrome. National guidelines dictate that at the time of the patient's presentation to an emergency department, these therapies should be given expeditiously, whether or not percutaneous coronary intervention is planned.
In this issue of the Journal, Mehta et al. report on the results of the Clopidogrel and Aspirin Optimal Dose Usage to Reduce Recurrent Events–Seventh Organization to Assess Strategies in Ischemic Syndromes (CURRENT–OASIS 7) trial, which evaluated alternative dosing regimens for both of these agents.1
Weblink here |
|
2010 Oct 15 & 16 - Medico-Legal Course |
|
|
|
|
Activity Schedules and Reports -
Local Meetings (Others)
|
Co-organized by Hong Kong Society for Emergency Medicine & Surgery and Association of Hong Kong Nursing Staff
Speaker: Dr. Catherine Tay – Associate Professor, School of Business, National University of Singapore
Period: 16/10/2010 (Sat, total 1session), 8:30am – 5:30pm
Venue: Lecture Theatre, G/F, Wai Oi Block, Caritas Medical Center
Understanding of medical law is increasingly important for all doctors, nurses and health professionals. This one day course will provide the essentials of medical law. Ignorance of the law is not a Privilege. It is your Misfortune! The course will provide what you need to know and be aware of the medico-legal issues faced in health care.
|
|
Last Updated on Thursday, 02 September 2010 11:45 |
|
Read more...
|
|
CCM and ICM Development -
Critical Care Medicine Foundation Development
|
|
The Critical Care Medicine Foundation (CCMF) of the HKSCCM would like to express our gratitude to the following companies/individuals for their contributions. Click Read More. |
|
Last Updated on Tuesday, 31 August 2010 20:19 |
|
Read more...
|
|
2010 Oct 14 to 15 - Em ECHO Course – Seminars & Workshops – TSK Hosp |
|
|
|
|
Activity Schedules and Reports -
Local Meetings (Others)
|
Date: 14 – 15 Oct 2010 (Thu – Fri) 9a – 5p; Target participants: HA Doctors & Nurses (Acute / Emergency / Critical Care Units) - # 2; Commissioned Training Programme of COC (A&E), HAHO < IT Registration Support – TMH CSTC >
Em ECHO is evolving to become the bed-side visual stethoscope of the clinician a POCT to visualize the anatomy & assess the functions to reveal the abnormality to expedite the early Dx with aetiology identification of cardiac diseases (pericardial collection due to pericarditis or traumatic hemopericardium, AMI, dissecting aortic aneurysm, valvular lesions, IVC status and the probable causes of cardiac arrest or shock).
|
|
Read more...
|
|
|
|
